-+ 0.00%
-+ 0.00%
-+ 0.00%
Clene Seeks FDA Accelerated Approval for CNM-Au8 in ALS
Share
Listen to the news
Clene Seeks FDA Accelerated Approval for CNM-Au8 in ALS
  • Clene submitted an FDA application in October 2026 seeking accelerated approval of CNM-Au8 for amyotrophic lateral sclerosis.
  • The application is based on neurofilament light chain biomarker data and clinical outcomes.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Clene Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610190800PRIMZONEFULLFEED9846985) on October 19, 2026, and is solely responsible for the information contained therein.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending